[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100313867":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":30,"centralContacts":35,"locations":41,"responsibleParty":100,"collaborators":25,"id":103,"slug":104,"hasResults":105,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":109,"eligibilityCriteria":110,"healthyVolunteers":105,"sex":111,"minAge":112,"maxAge":113,"enrollmentInfo":114,"targetDuration":25,"studyType":117,"phases":118,"briefSummary":120,"conditions":121,"keywords":124,"overallStatus":44,"whyStopped":25,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":135},{"fullName":5,"class":6},"AC Camargo Cancer Center","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Sentinel Node Mapping plus Lymphadenectomy","ACTIVE_COMPARATOR","Patients with high risk endometrial cancer will undergo Sentinel Node Mapping followed by Systematic Pelvic and Para-Aortic Lymphadenectomy",[13,14],"Procedure: Sentinel Node Mapping","Procedure: Lymphadenectomy",{"label":16,"type":17,"description":18,"interventionNames":19},"Sentinel Node Mapping","EXPERIMENTAL","Patients with high risk endometrial cancer will undergo Sentinel Node Mapping per NCCN algorithm",[13],[21,26],{"type":22,"name":16,"description":23,"armGroupLabels":24,"otherNames":25},"PROCEDURE","At least one sentinel node should be retrieved in both hemipelvis. If no sentinel node is found in one hemipelvis, a side specific lymphadenectomy will be performed.",[16,9],null,{"type":22,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"Lymphadenectomy","Systematic Pelvic and Para-Aortic Lymphadenectomy",[9],[31],{"name":32,"affiliation":33,"role":34},"Glauco Baiocchi, MD, PhD","Department of Gynecologic Oncology - AC Camargo Cancer Center","PRINCIPAL_INVESTIGATOR",[36],{"name":37,"role":38,"phone":39,"phoneExt":25,"email":40},"Bruna Goncalves, RN, MSc","CONTACT","551121895110","bruna.goncalves@accamargo.org.br",[42,59,72,82,91],{"facility":43,"status":44,"city":45,"state":46,"zip":25,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"Hospital Erasto Gaertner","RECRUITING","Curitiba","Paraná","Brazil","BR",{"type":50,"coordinates":51},"Point",[52,53],-49.27306,-25.42778,{"lat":53,"lon":52},[56],{"name":57,"role":38,"phone":25,"phoneExt":25,"email":58},"Reitan Ribeiro, MD","reitanribeiro@hotmail.com",{"facility":60,"status":44,"city":61,"state":62,"zip":25,"country":47,"countryCode":48,"cosmosGeoPoint":63,"geoPoint":67,"contacts":68},"Hospital do Cancer de Barretos","Barretos","São Paulo",{"type":50,"coordinates":64},[65,66],-48.56778,-20.55722,{"lat":66,"lon":65},[69],{"name":70,"role":38,"phone":25,"phoneExt":25,"email":71},"Carlos Andrade, MD, PhD","mdcarlosandrade@gmail.com",{"facility":5,"status":44,"city":62,"state":62,"zip":73,"country":47,"countryCode":48,"cosmosGeoPoint":74,"geoPoint":78,"contacts":79},"01509010",{"type":50,"coordinates":75},[76,77],-46.63611,-23.5475,{"lat":77,"lon":76},[80],{"name":32,"role":38,"phone":39,"phoneExt":25,"email":81},"glauco.baiocchi@accamargo.org.br",{"facility":83,"status":44,"city":62,"state":62,"zip":25,"country":47,"countryCode":48,"cosmosGeoPoint":84,"geoPoint":86,"contacts":87},"Albert Einstein Hospital",{"type":50,"coordinates":85},[76,77],{"lat":77,"lon":76},[88],{"name":89,"role":38,"phone":25,"phoneExt":25,"email":90},"Renato Moretti-Marques, MD, PhD","morettimarques@gmail.com",{"facility":92,"status":44,"city":62,"state":62,"zip":25,"country":47,"countryCode":48,"cosmosGeoPoint":93,"geoPoint":95,"contacts":96},"Sao Camilo Oncologia",{"type":50,"coordinates":94},[76,77],{"lat":77,"lon":76},[97],{"name":98,"role":38,"phone":25,"phoneExt":25,"email":99},"Andre Lopes, MD, PhD","andrelopes.cirurgia@gmail.com",{"type":34,"investigatorFullName":101,"investigatorTitle":102,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"Glauco Baiocchi Neto","Director, Department of Gynecologic Oncology","100313867","sentinel-node-mapping-in-high-risk-endometrial-cancer-100313867",false,"NCT03366051","Sentinel Node Mapping in High Risk Endometrial Cancer","Sentinel Node Mapping Versus Sentinel Node Mapping With Systematic Lymphadenectomy in High Risk Endometrial Cancer: a Open Label, Non-inferiority, Randomized Trial.","ALICE","Inclusion Criteria:\n\n* High grade histologies (endometrioid grade 3, serous, clear cell and carcinosarcoma)\n* Endometrioid grades 1 or 2 with myometrial invasion of ≥50%\n* Endometrioid grades 1 or 2 with cervical invasion\n* Clinically suitable to receive systematic lymphadenectomy\n* Consent statement\n\nExclusion Criteria:\n\n* Previous hysterectomy in other institution\n* Presence of extra-uterine disease (peritoneal, visceral or suspicious lymph node metastasis)\n* Previous pelvic node dissection","FEMALE","18 Years","75 Years",{"count":115,"type":116},178,"ESTIMATED","INTERVENTIONAL",[119],"NA","This study will evaluate the role of systematic lymphadenectomy after sentinel node (SLN) mapping in high risk endometrial cancer (high grade histologies or deep myometrial invasion). The participants will be randomized in a non-inferiority controlled trial in 2 groups: SLN mapping or SLN mapping followed by systematic lymphadenectomy.",[122,123],"Endometrial Cancer","Lymph Node Metastases",[122,125,27],"Sentinel Lymph Node","2024-07-29",{"date":128,"type":129},"2024-07-30","ACTUAL",{"date":131,"type":129},"2017-12-22",{"date":133,"type":116},"2024-12-20",{"name":5,"class":6},5]